Abstract
Neurocysticercosis is an important cause of seizures worldwide and is endemic in most of Latin America, Sub-Saharan Africa, Southeast Asia, India, and China. Neurocysticercosis has profoundly different disease manifestations varying from asymptomatic presentation to life-threatening hydrocephalus. Clinical manifestations, pathogenesis, diagnostic methods, and optimal treatment vary with the location, number of lesions, and host response. Diagnosis is based on a combination of clinical presentation, neuroimaging findings, history of exposure, and serologic testing. Initial therapy should be focused on symptom management including seizure control and management of increased intracranial pressure. Emerging data are demonstrating that the optimal management approach varies with stage. Single enhancing or cystic lesions should be treated with albendazole and steroids. Patients with more than two cystic lesions should be treated with combination therapy with albendazole and praziquantel, whereas patients with hydrocephalus benefit from surgical management, especially with minimally invasive approaches.
| Original language | English (US) |
|---|---|
| Article number | 44 |
| Journal | Current Infectious Disease Reports |
| Volume | 18 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 1 2016 |
Fingerprint
Keywords
- Albendazole
- Cysticercosis
- Neurocysticercosis
- Praziquantel
- Taenia solium
ASJC Scopus subject areas
- Infectious Diseases
Cite this
Update on the Diagnosis and Management of Neurocysticercosis. / Webb, Camille M.; White, A. Clinton.
In: Current Infectious Disease Reports, Vol. 18, No. 12, 44, 01.12.2016.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Update on the Diagnosis and Management of Neurocysticercosis
AU - Webb, Camille M.
AU - White, A. Clinton
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Neurocysticercosis is an important cause of seizures worldwide and is endemic in most of Latin America, Sub-Saharan Africa, Southeast Asia, India, and China. Neurocysticercosis has profoundly different disease manifestations varying from asymptomatic presentation to life-threatening hydrocephalus. Clinical manifestations, pathogenesis, diagnostic methods, and optimal treatment vary with the location, number of lesions, and host response. Diagnosis is based on a combination of clinical presentation, neuroimaging findings, history of exposure, and serologic testing. Initial therapy should be focused on symptom management including seizure control and management of increased intracranial pressure. Emerging data are demonstrating that the optimal management approach varies with stage. Single enhancing or cystic lesions should be treated with albendazole and steroids. Patients with more than two cystic lesions should be treated with combination therapy with albendazole and praziquantel, whereas patients with hydrocephalus benefit from surgical management, especially with minimally invasive approaches.
AB - Neurocysticercosis is an important cause of seizures worldwide and is endemic in most of Latin America, Sub-Saharan Africa, Southeast Asia, India, and China. Neurocysticercosis has profoundly different disease manifestations varying from asymptomatic presentation to life-threatening hydrocephalus. Clinical manifestations, pathogenesis, diagnostic methods, and optimal treatment vary with the location, number of lesions, and host response. Diagnosis is based on a combination of clinical presentation, neuroimaging findings, history of exposure, and serologic testing. Initial therapy should be focused on symptom management including seizure control and management of increased intracranial pressure. Emerging data are demonstrating that the optimal management approach varies with stage. Single enhancing or cystic lesions should be treated with albendazole and steroids. Patients with more than two cystic lesions should be treated with combination therapy with albendazole and praziquantel, whereas patients with hydrocephalus benefit from surgical management, especially with minimally invasive approaches.
KW - Albendazole
KW - Cysticercosis
KW - Neurocysticercosis
KW - Praziquantel
KW - Taenia solium
UR - http://www.scopus.com/inward/record.url?scp=84994051898&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994051898&partnerID=8YFLogxK
U2 - 10.1007/s11908-016-0547-4
DO - 10.1007/s11908-016-0547-4
M3 - Review article
VL - 18
JO - Current Infectious Disease Reports
JF - Current Infectious Disease Reports
SN - 1523-3847
IS - 12
M1 - 44
ER -